Vaccination Against Shared Neoantigens Induced in Recurrent & Future Tumors

Time: 9:30 am
day: Day Two


  • Common neoantigens are induced in disseminated tumor lesions and resident dendritic cells by targeted siRNA inhibition of the peptide transporter TAP
  • Using broadly applicable chemically synthesized oligonucleotides to vaccinate against induced neoantigens which inhibits tumor growth in recurrent and premalignant models
  • Vaccination against induced neoantigens will benefit the 70-80% of cancer patients that do not express or express too few mutation-derived neoantigens